A Phase 1, Randomized, Placebo-controlled, Double Blind, Single, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ANX005 Monotherapy and ANX005 in Combination With IVIg in Healthy Volunteers

Trial Profile

A Phase 1, Randomized, Placebo-controlled, Double Blind, Single, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ANX005 Monotherapy and ANX005 in Combination With IVIg in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs ANX 005 (Primary)
  • Indications Autoimmune disorders; CNS disorders
  • Focus Adverse reactions
  • Sponsors Annexon
  • Most Recent Events

    • 03 Jan 2017 Status changed from planning to recruiting.
    • 03 Oct 2016 New trial record
    • 19 Sep 2016 According to Annexon Biosciences media release, company plans to initiate this study in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top